Palabras clave
Candida sp
leveduras
fungos e infecção hospitalar
Cómo citar
Resumen
O citral, componente do óleo essencial de Cymbopogon citratus, tem sido pesquisado para verificar sua ação antimicrobiana em bactérias e fungos. Com o objetivo de avaliar a atividade antifúngica do citral contra leveduras do gênero Candida, no presente trabalho foram avaliadas 32 amostras de Candida albicans, 25 de C. tropicalis, 20 de C. parapsilosis e 5 de C. glabrata, coletadas de pacientes hospitalizados. O citral foi testado nas concentrações de 10%, 15%, 25%, 35%, 50% e 60% (v/v), utilizando a técnica de difusão em ágar Sabouraud. A atividade antifúngica do citral foi constatada em todas as leveduras selecionadas nas concentrações ≥ 25%. Mediante os resultados obtidos, sugere-se a realização de novas pesquisas sobre citral frente às demais espécies de fungos patogênicos para conhecer as características toxicológicas e farmacológicas para que esse componente possa futuramente ser utilizado como um importante princípio ativo na produção de novos agentes antifúngicos.
Citas
1. Rang HP, Dale MM, Ritter JM. Farmacologia. 5th ed. Rio de Janeiro: Elsevier ; 2004.
2. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 2001; 39 (9): 3254-9.
3. Colombo AL, Nucci M, Salomão R, Branchini MLM, Richtmann R, Derossi A, et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999; 34(4): 281-6.
4. Crocco EI, Mimica LMJ, Muramatu LH, Garcia C, Souza VL, Ruiz LRB, et al. Identifi cação de espécies de Candida e susceptibilidade antifúngica in vitro: estudo de 100 pacientes com candidíases superfi ciais. An Bras Dermatol 2004; 79(6): 689-97.
5. Hazen KC, Baron EJ, Colombo AL, Girmenia C, Sanchez-Souza A, Palacio A, et al. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol 2003; 41(12): 5623-32.
6. Bougnoux ME, Kac G, Aegerter P, D’enfert C, Fagon JY, CandiRea Study Group. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med 2008; 34 (2): 292-9.
7. Horn DL, Fishman JA, Steinbach WJ, Anaissie EJ, Marr KA, Olyaei AJ, et al. Presentation of the PATH Alliance® registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007; 59(4): 407-14.
8. Jordà-Marcos R, Alvarez-Lerma F, Jurado M, Palomar M, Nolla-Salas J, León MA, et al. Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses 2007; 50(4): 302-10.
9. Lagrou K, Verhaegen J, Peetermans WE, De Rijdt T, Maertens J, Van Wijngaerden E. Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species. Eur J Clin Microbiol Infect Dis 2007; 26(8): 541-7.
10. Odds FC, Hanson MF, Davidson AD, Jacobsen MD, Wright P, Whyte JA, et al. One year prospective survey of Candida bloodstream infections in Scotland. J Med Microbiol 2007; 56: 1066-75.
11. Antunes AGV, Pasqualotto AC, Diaz MC, D ́Azevedo A, Severo LC. Candidemia in a brazilian tertiary care hospital: species distribution and antifungal susceptibility patterns. Rev Inst Med Trop São Paulo 2004;46(5): 239-41.
12. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43.
13. da Matta DA, De Almeida LP, Machado AM, Azevedo AC, Kusano EJ, Travassos NF, et al. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in São Paulo, Brazil, 1995–2003. Diagn Microbiol Infect Dis 2007; 57(4): 399-404.
14. Colombo AL, Nucci M, Park BJ, Nouér SA, Arthington-Skaggs B, da Matta DA, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006; 44(8): 2816-23.
15. Shen YZ, Qi TK, Ma JX, Jiang XY, Wang JR, Xu QN, et al. Invasive fungal infections among inpatients with acquired immune defi ciency syndrome at a Chinese university hospital. Mycoses 2007; 50: 475-80.
16. Lima EO, Farias NMP, et al. Atividade antifúngica de óleos essenciais, obtidos de plantas medicinais, contra leveduras do gênero Candida. R Bras Ci Saúde 1999; 3(1/3): 51-64.
17. Schuck VJA, Fratini M, Rauber CS, Henriques A, Schapoval EES. Avaliação da atividade antimicrobiana de Cymbopogon citratus. Rev Bras Ciên Farm 2001; 37(1): 45-9.
18. Cimanga K, Kambu K, Tona L, Apers S, De Bruyne T, Hermans N, et al. Correlation between chemical composition and antibacterial activity of essential oils of some aromatic medicinal plants growing in the Democratic Republic of Congo. J Ethnopharmacol 2002; 79: 213-20.
19. Onawunmi GO. Evaluation of the antifungal activity of lemon grass oil. Int J Crude Drug Res 1989;27(2): 121-6.
20. Lewinsohn E, Dudai N, Tadmor Y, Katzir I, Ravid U, Putievsky E, et al. Histochemical localization of citral accumulation in lemongrass leaves (Cymbopogon citratus (DC.) Stapf., Poaceae. Ann Bot (Lond) 1998; 81: 35-9.
21. Saleem M, Afza N, Anwar MA, Hai SM, Ali MS. A comparative study of essential oils of Cymbopogon citratus and some members of the genus Citrus. Nat Prod Res 2003; 17(5): 369-73.
22. Hayes AJ, Markovic B. Toxicity of Australian essential oil Backhousia citriodora (Lemon myrtle). Part 1. Antimicrobial activity and in vitro cytotoxicity. Food Chem Toxicol 2002; 40(4): 535-43.
23. Luo M, Jiang LK, Huang YX, Xiao M, Li B, Zou GL. Effects of citral on Aspergillus fl avus spores by quasi-elastic light scattering and multiplex microanalysis techniques. Acta Biochim Biophys Sin 2004; 36(4): 277-83.
24. Souza EL, Lima EO, Freire KRL, Sousa CP. Inhibitory action of some essential oils and phytochemicals on the growth of various moulds isolated from foods. Braz Arch Biol Technol 2005; 48(2): 245-50.
25. Miranda ET, Silva RAM, Fusco-almeida AM, Melhem MSC, Pukinskas SR, Mendes-Giannini MJS. Epidemiologia de candidíase hospitalar: a importância da identifi cação específi ca. Rev Ciênc Farm 2003; 24(1): 39-45.
26. Oliveira RDR, Maffei CML, Martinez R Infecção urinária hospitalar por leveduras do gênero Candida. Rev Assoc Med Bras 2001; 47 (3): 231-5.
27. Godoy P, Tiraboschi NI, Severo LC, Bustamante B, Calvo B, Almeida LP, et al. Species distribution and antifungal susceptibility profi le of Candida spp. bloodstream isolates from Latim American hospitals. Mem Inst Oswaldo Cruz 2003; 98(3): 401-5.
28. Silva VV, Diaz MCJ, Febré N. Vigilancia de la resistencia de levaduras a antifúngicos. Rev Chil Infect 2002; 19 (Suppl 2): 149-56.
29. Silva CB, Guterres SS, Weisheimer V, Schapoval EES. Antifungal activity of the lemongrass oil and citral against Candida spp. The Brazilian Journal of Infectious Diseases 2008; 12(1): 63-6.
30. Abe S, Sato Y, Inoue S, Ishibashi H, Maruyama N, Takizawa T, et al. Anti-Candida albicans activity of essential oils including lemongrass (Cymbopogon citratus) oil and its component, citral. Jpn J Med Mycol 2003; 44(4): 285-91.
31. Onawunmi GO. Evaluation of the antimicrobial activity of citral. Letters in applied microbiology 1989;9: 105-8.
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Derechos de autor 2009 Revista del Instituto Adolfo Lutz